国务院联防联控机制科研攻关组相关负责人表示，国家已批准将新冠疫苗紧急使用年龄范围扩大到3岁以上。

China is expected to administer COVID-19 vaccinesto at least 70 percent of the target population by the end of this year, an official from the National Health Commission confirmed, as the country continues to rampup its inoculationdrive to approve the emergency use of COVID-19 vaccines for those agedbetween 3 and 17 years old.

我国继续推进新冠疫苗接种工作，已批准将3-17岁人群纳入新冠疫苗紧急使用年龄范围。国家卫健委相关负责人表示，预计到今年年底前，我国将完成至少70%的目标人群接种。

Preliminary results from Phase I and II clinical trials showed the vaccinecould trigger immune response in three to 17 year-old participants, and most adversereactions were mild.

Ⅰ/Ⅱ期临床试验初步结果显示，疫苗能够触发3到17岁接种者体内的免疫反应，多数不良反应轻微。

Following approval by relevant authorities, vaccinationwill be open to people in this age group based on the epidemicprevention and control situation .

经国家有关部门批准后，会根据疫情防控需要在这一人群中推动接种。

年龄最大接种者超过100岁

Over 763 million doses of COVID-19 vaccines had been administered across China as of Saturday, NHC figures showed.

国家卫健委发布的数据显示，截至6月5日，我国新冠疫苗接种已超过7.63亿剂次。

The oldest vaccine recipientsin China's vaccination campaign, open to people aged over 18, are more than 100 years old.

目前我国新冠疫苗接种面向18岁以上人群，其中年龄最大的接种者超过100岁。

China is also making headway in creating nasal spray and inhaledCOVID-19 vaccines as clinical trials of them are underway, and experts will study their safety and efficacy after completing the collection of relevant data.

我国在鼻喷雾式 / 吸入型新冠疫苗研发方面也有新进展，目前这种疫苗正在进行临床试验。相关数据收集完成后，专家将对其安全性和有效性展开研究。